A randomized trial of 2,487 prostate cancer patients found that those referred to heart specialists achieved significantly better cholesterol control, with levels averaging 12 mg/dL lower than usual care patients. According to Gram Research analysis, the specialist-led intervention used aggressive statin therapy and blood pressure management to improve risk factor control. However, the study found no clear difference in actual heart attacks, strokes, or heart failure between groups, meaning it remains uncertain whether better risk factor control prevented serious heart events.
Researchers studied whether prostate cancer patients should see a heart specialist to better manage their cardiovascular health. They followed nearly 2,500 men over almost 6 years, with half receiving routine visits to a heart doctor who helped them control blood pressure and cholesterol levels. According to Gram Research analysis, the men who saw heart specialists had significantly better cholesterol control and lower cholesterol levels overall. However, the study found it’s still unclear whether these improvements actually prevented heart attacks, strokes, or other serious heart events. The findings suggest that specialized heart care may help prostate cancer patients manage risk factors, though more research is needed to confirm whether this translates to fewer heart problems.
Key Statistics
A 2026 randomized controlled trial of 2,487 prostate cancer patients found that those referred to heart specialists achieved cholesterol levels 12 mg/dL lower than patients receiving usual care alone, primarily through more aggressive statin use.
In the same trial with nearly 6 years of follow-up, the intervention group showed a 60% better chance of improved combined cardiovascular outcomes (win ratio 1.60), though there was no statistically significant difference in actual heart attacks, strokes, or heart failure between groups.
Heart specialists in the trial prescribed statin medications to all prostate cancer patients regardless of baseline cholesterol levels, a more aggressive approach than typical guideline-based practice, resulting in sustained cholesterol improvements over the study period.
The Quick Take
- What they studied: Whether prostate cancer patients who see a heart specialist have better control of heart disease risk factors and fewer heart problems compared to those receiving regular care only.
- Who participated: 2,487 men with prostate cancer, averaging 68 years old, from 55 medical centers across 8 countries. All were either newly diagnosed with prostate cancer or starting hormone therapy treatment.
- Key finding: Men who saw heart specialists achieved significantly better cholesterol control, with cholesterol levels averaging 12 mg/dL lower than the control group. However, there was no clear difference in actual heart attacks, strokes, or heart failure between the two groups during the nearly 6-year study.
- What it means for you: If you have prostate cancer, seeing a heart specialist may help you better manage cholesterol and blood pressure through more aggressive treatment strategies. However, it remains uncertain whether this directly prevents serious heart events. Discuss with your doctor whether specialist referral is appropriate for your individual situation.
The Research Details
This was a randomized controlled trial, which is considered one of the strongest types of medical research. Researchers randomly assigned 2,487 prostate cancer patients to two groups: one group received their usual medical care, while the other group received usual care plus a referral to a heart specialist (either an internist or cardiologist). The study took place across 55 medical centers in 8 countries between 2015 and 2025, with patients followed for an average of nearly 6 years.
The heart specialists who saw the intervention group patients provided systematic care focused on three main goals: getting systolic blood pressure to 130 mm Hg or lower, prescribing statin medications to lower cholesterol (regardless of baseline cholesterol levels), and providing advice on smoking cessation, diet, and exercise. This approach was more aggressive than typical guideline-based care, as specialists prescribed statins to all patients, even those with normal cholesterol levels.
Researchers tracked multiple outcomes including serious heart events (heart attacks, strokes, heart failure, and cardiovascular death) as well as risk factor control (cholesterol and blood pressure levels). They used a statistical method called the “win ratio” to compare overall outcomes between groups, which accounts for multiple different outcomes simultaneously.
Prostate cancer patients face unique cardiovascular challenges because hormone therapy treatments can increase heart disease risk factors like high blood pressure and high cholesterol. Many patients don’t receive adequate treatment for these risk factors under standard care. This study tested whether specialized heart care could better manage these risks in this vulnerable population. Understanding whether specialist referral improves outcomes helps doctors decide how to best organize care for cancer patients with heart disease risk.
This study has several strengths: it’s a randomized controlled trial (the gold standard for research), included a large sample size (2,487 patients), followed participants for nearly 6 years, and involved multiple international sites, making results more generalizable. However, the study was conducted in specialized medical centers, so results may not apply to all healthcare settings. Additionally, the intervention was quite intensive and may not be feasible in all clinical practices. The fact that researchers found improved risk factor control but no clear reduction in actual heart events suggests the study may need to continue longer or involve more patients to detect differences in serious outcomes.
What the Results Show
The intervention group (those who saw heart specialists) achieved significantly better cholesterol control compared to the usual care group. On average, patients in the intervention group had cholesterol levels that were 12 mg/dL lower than those in the control group. This improvement was primarily due to the heart specialists prescribing statin medications more aggressively, they gave statins to all patients, even those with normal cholesterol levels, which is more intensive than typical practice.
Blood pressure control was similar between groups, with the intervention group averaging 131.1 mm Hg systolic blood pressure and the control group averaging 132.9 mm Hg. While this difference favors the intervention group, it’s relatively small and both groups came close to the target of 130 mm Hg or lower.
When researchers combined all the outcomes they were measuring (using the win ratio method), they found the intervention group had better overall results, with a win ratio of 1.60 in favor of the specialist referral group. This means the intervention group had a 60% better chance of having better combined outcomes across all measured factors.
However, when looking at serious heart events specifically, heart attacks, strokes, heart failure, and cardiovascular death: there was no statistically significant difference between groups. The hazard ratio was 1.08, which means the intervention group actually had slightly more events, though this difference could easily be due to chance.
The study found that the aggressive statin strategy used by heart specialists was the main driver of improved outcomes in the intervention group. Even patients with normal cholesterol levels who received statins benefited from lower cholesterol levels. The study also showed that implementing a systematic, protocol-driven approach to cardiovascular risk management in specialist clinics was feasible and could be sustained over many years. The consistency of results across multiple international sites suggests the findings may apply broadly to prostate cancer patients in developed healthcare systems.
Previous research has shown that prostate cancer patients have higher rates of cardiovascular disease and that hormone therapy increases cardiovascular risk. This study builds on that knowledge by testing whether intensive specialist-led risk factor management can improve outcomes. The finding that risk factor control improved but serious events didn’t decrease differs from some cardiovascular prevention studies in other populations, where better risk factor control typically translates to fewer heart events. This suggests that either the study period wasn’t long enough to see event reduction, or that the relationship between risk factors and events may be different in prostate cancer patients receiving hormone therapy.
The most important limitation is that while risk factor control improved, there was no clear reduction in actual heart attacks, strokes, or heart failure. This makes it unclear whether the improved cholesterol control actually prevented serious heart problems. The study involved specialized medical centers with experienced cardiologists and internists, so results may not apply to regular primary care settings with fewer resources. Additionally, the intervention was quite intensive and time-consuming, which may not be practical for all healthcare systems. The study also primarily included patients in developed countries with good access to healthcare, so results may not apply to other populations. Finally, researchers noted that the study may need to continue longer or involve more patients to definitively determine whether specialist referral reduces serious cardiovascular events.
The Bottom Line
For prostate cancer patients starting hormone therapy: Consider asking your doctor about referral to a heart specialist or cardiologist, particularly if you have multiple cardiovascular risk factors. The evidence suggests this may help improve cholesterol and blood pressure control. However, it remains uncertain whether this directly prevents heart attacks or strokes, so discuss with your doctor whether specialist care is appropriate for your individual situation. For healthcare systems: Implementing systematic cardiovascular risk management protocols for prostate cancer patients appears feasible and improves risk factor control, though the clinical benefit in terms of preventing serious heart events needs further study.
This research is most relevant to men with prostate cancer who are starting or receiving hormone therapy (androgen deprivation therapy), as these patients face elevated cardiovascular risk. It’s particularly important for those with existing cardiovascular risk factors like high blood pressure or high cholesterol. Primary care doctors and cardiologists should consider this evidence when deciding whether to refer prostate cancer patients for specialized cardiovascular care. Patients should not assume they need specialist referral automatically, but should discuss their individual risk factors with their doctor.
Cholesterol improvements from specialist-led care appeared relatively quickly, within the first months of treatment. However, determining whether these improvements prevent serious heart events requires longer follow-up, this study tracked patients for nearly 6 years and still didn’t find a clear reduction in heart attacks or strokes. Patients should expect ongoing management and monitoring rather than quick fixes, and should continue lifestyle changes (diet, exercise, smoking cessation) alongside any medications prescribed.
Frequently Asked Questions
Should prostate cancer patients see a cardiologist to prevent heart disease?
Research shows that cardiologist referral improves cholesterol and blood pressure control in prostate cancer patients through aggressive medication management. However, it’s unclear whether this actually prevents heart attacks or strokes. Discuss with your doctor whether specialist referral is appropriate based on your individual cardiovascular risk factors.
Does hormone therapy for prostate cancer increase heart disease risk?
Yes, hormone therapy (androgen deprivation therapy) increases cardiovascular risk factors like high blood pressure and high cholesterol in prostate cancer patients. This is why cardiovascular monitoring and management are important for men receiving this treatment.
What cardiovascular targets should prostate cancer patients aim for?
Based on this research, prostate cancer patients should target a systolic blood pressure of 130 mm Hg or lower and total cholesterol of 155 mg/dL or lower. These targets may require statin therapy and blood pressure medications, which should be discussed with your doctor.
How long does it take to see benefits from specialist cardiovascular care?
Cholesterol improvements from specialist-led care appear within months through medication adjustments. However, determining whether these improvements prevent serious heart events requires years of follow-up. This study tracked patients for nearly 6 years and is still uncertain about event prevention.
Can lifestyle changes alone manage cardiovascular risk in prostate cancer patients?
Lifestyle changes like diet, exercise, and smoking cessation are important, but this research shows that prostate cancer patients typically need medications (statins and blood pressure drugs) to adequately control cardiovascular risk factors, particularly when receiving hormone therapy.
Want to Apply This Research?
- Track weekly systolic blood pressure readings and monthly total cholesterol levels if available from lab work. Set target goals of systolic BP ≤130 mm Hg and total cholesterol ≤155 mg/dL, and log progress toward these targets.
- If referred to a heart specialist, use the app to set reminders for specialist appointments and to track adherence to prescribed medications (particularly statins). Log any lifestyle changes recommended by the specialist, such as dietary modifications or exercise routines, and monitor consistency week-to-week.
- Create a long-term dashboard showing trends in blood pressure and cholesterol over 3-6 month periods. Share this data with both your primary care doctor and any heart specialists involved in your care. Set quarterly check-in reminders to review whether targets are being met and adjust behaviors or medications as needed.
This research summary is for educational purposes only and should not replace professional medical advice. Prostate cancer patients should discuss cardiovascular risk management, specialist referral, and medication decisions with their oncologist and primary care physician. The findings suggest specialist referral may improve risk factor control, but do not definitively prove it prevents heart attacks or strokes. Individual treatment decisions should be based on personal risk factors, medical history, and professional medical guidance. Always consult with qualified healthcare providers before making changes to cancer treatment or cardiovascular management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
